Mark Goldsmith

The RAS rush: Rev­o­lu­tion Med­i­cines bags re­mark­able $238M IPO raise, more than dou­bling orig­i­nal goal

Rev­o­lu­tion Med­i­cines made it.

Less than a month af­ter pen­cilling in $100 mil­lion for its IPO — di­vulging some de­tails about its for­ay in­to the red hot KRAS race along the way — the biotech is go­ing home with $238 mil­lion raised and a new tick­er on the Nas­daq: $RVMD.

It did so by of­fer­ing 14 mil­lion shares at $17 each, the top of the range af­ter the biotech re­vised its terms. Not that its orig­i­nal goal wasn’t al­ready am­bi­tious, aim­ing be­tween $14 and $16 for 10 mil­lion shares.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.